ER-positive breast cancer cells are poised for RET-mediated endocrine resistance
S. Horibata, E. J. Rice, H. Zheng, L. J. Anguish, S. Coonrod, C. G. Danko
This study shows that ER+ breast cancer cells have the RET signaling pathway components but lack RET ligands needed for endocrine resistance, linking RET ligand expression to therapy response and survival.
bioRxiv · Sep 21, 2017Cancer Biology